| Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
82 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Ulcerative Colitis
|
827 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||||
Stomach Carcinoma
|
652 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Stage IV Gallbladder Cancer AJCC v8
|
56 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||
Stage III Gallbladder Cancer AJCC v8
|
56 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||
Stage IIB Gallbladder Cancer AJCC v8
|
56 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||
Stage IIA Gallbladder Cancer AJCC v8
|
56 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||
Stage 0 Gallbladder Cancer AJCC v8
|
56 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||
Squamous cell carcinoma of the head and neck
|
348 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1 | 2016 | 2016 | |||||||
Prostate carcinoma
|
1168 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.020 | 0.500 | 2 | 2008 | 2011 | ||||||
Primary malignant neoplasm of lung
|
981 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.020 | 1.000 | 2 | 2012 | 2018 | ||||||
Primary malignant neoplasm
|
1374 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.020 | 1.000 | 2 | 2011 | 2013 | ||||||
Pain
|
196 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.030 | 1.000 | 3 | 2009 | 2015 | ||||||
Ovarian Carcinoma
|
19 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||||
Non-Small Cell Lung Carcinoma
|
712 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
Nasopharyngeal carcinoma
|
320 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Metastatic Renal Cell Carcinoma
|
9 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Metastatic Renal Cell Cancer
|
9 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Malignant tumor of cervix
|
245 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||||
Malignant Neoplasms
|
1641 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.030 | 1.000 | 3 | 2011 | 2013 | ||||||
Malignant neoplasm of stomach
|
615 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Malignant neoplasm of prostate
|
1082 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.020 | 0.500 | 2 | 2008 | 2011 | ||||||
Malignant neoplasm of ovary
|
315 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||||
Malignant neoplasm of mouth
|
184 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.010 | 1 | 2015 | 2015 | |||||||
Malignant neoplasm of lung
|
1142 | 0.583 | 0.560 | 1 | 186673926 | 3 prime UTR variant | A/G;T | snv | 0.020 | 1.000 | 2 | 2012 | 2018 |